search
Back to results

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Primary Purpose

Agitation, Dementia

Status
Active
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
BXCL501
Matching Placebo
Sponsored by
BioXcel Therapeutics Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Agitation

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AA criteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria Episodes of psychomotor agitation (e.g., kick, bite, flailing) Subjects exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to full assistance with activities of daily living Subjects who read, understand, and provide written informed consent, or who have a LAR to provide consent on their behalf Subjects who are deemed to be medically appropriate for study participation by the principal investigator Participants who agree to use a medically acceptable and effective birth control method Exclusion Criteria: Subjects with dementia or other memory impairment not due to probable AD. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function. Subjects with agitation caused by acute intoxication. Subjects with significant risk of suicide or homicide per the investigator's assessment. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (>5 years) history of stroke may be included, regardless of size/location. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia. Subjects with laboratory or ECG abnormalities. Subjects who have received an investigational drug within 30 days prior to Screening. Subjects who are currently suffering from substance abuse. Subjects with a potential cause for delirium (relatively recent onset agitation and dementia)

Sites / Locations

  • BioXcel Clinical Research Site
  • BioXcel Clinical Research Site
  • BioXcel Clinical Research Site
  • BioXcel Clinical Research Site
  • BioXcel Clinical Research Site
  • BioXcel Clinical Research Site
  • BioXcel Clinical Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Cohort 1- 40 Micrograms

Cohort 2- 60 Micrograms

Placebo

Arm Description

Sublingual film containing 40 Micrograms Dexmedetomidine

Sublingual film containing 60 Micrograms Dexmedetomidine

Sublingual Placebo film

Outcomes

Primary Outcome Measures

Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)

Secondary Outcome Measures

Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)

Full Information

First Posted
December 16, 2022
Last Updated
July 25, 2023
Sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT05665088
Brief Title
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
Official Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 14, 2022 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.
Detailed Description
A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female subjects (65 years and older) with acute psychomotor agitation associated with dementia. Approximately 150 subjects will participate in this study. Subjects will receive a single film consisting of BXCL501 40 µg dose or BXCL501 60 µg dose or placebo. Subjects must reside in a care facility where all study-related procedures and study drug dosing will be performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Agitation, Dementia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized
Masking
InvestigatorOutcomes Assessor
Masking Description
Double-Blinded
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1- 40 Micrograms
Arm Type
Experimental
Arm Description
Sublingual film containing 40 Micrograms Dexmedetomidine
Arm Title
Cohort 2- 60 Micrograms
Arm Type
Experimental
Arm Description
Sublingual film containing 60 Micrograms Dexmedetomidine
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Sublingual Placebo film
Intervention Type
Drug
Intervention Name(s)
BXCL501
Other Intervention Name(s)
Dexmedetomidine
Intervention Description
Sublingual Film
Intervention Type
Drug
Intervention Name(s)
Matching Placebo
Other Intervention Name(s)
Placebo
Intervention Description
Sublingual Placebo Film
Primary Outcome Measure Information:
Title
Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
Description
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time Frame
120 minutes post-dose for first episode of agitation
Secondary Outcome Measure Information:
Title
Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
Description
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time Frame
60 minutes post-dose for first episode of agitation
Title
Change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
Description
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time Frame
30 minutes post-dose for first episode of agitation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AA criteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria Episodes of psychomotor agitation (e.g., kick, bite, flailing) Subjects exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to full assistance with activities of daily living Subjects who read, understand, and provide written informed consent, or who have a LAR to provide consent on their behalf Subjects who are deemed to be medically appropriate for study participation by the principal investigator Participants who agree to use a medically acceptable and effective birth control method Exclusion Criteria: Subjects with dementia or other memory impairment not due to probable AD. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function. Subjects with agitation caused by acute intoxication. Subjects with significant risk of suicide or homicide per the investigator's assessment. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (>5 years) history of stroke may be included, regardless of size/location. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia. Subjects with laboratory or ECG abnormalities. Subjects who have received an investigational drug within 30 days prior to Screening. Subjects who are currently suffering from substance abuse. Subjects with a potential cause for delirium (relatively recent onset agitation and dementia)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Risinger, MD
Organizational Affiliation
BioXcel Therapeutics
Official's Role
Study Chair
Facility Information:
Facility Name
BioXcel Clinical Research Site
City
Los Alamitos
State/Province
California
ZIP/Postal Code
90720
Country
United States
Facility Name
BioXcel Clinical Research Site
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Facility Name
BioXcel Clinical Research Site
City
Maitland
State/Province
Florida
ZIP/Postal Code
32751
Country
United States
Facility Name
BioXcel Clinical Research Site
City
The Villages
State/Province
Florida
ZIP/Postal Code
32162
Country
United States
Facility Name
BioXcel Clinical Research Site
City
Marrero
State/Province
Louisiana
ZIP/Postal Code
70072
Country
United States
Facility Name
BioXcel Clinical Research Site
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01103
Country
United States
Facility Name
BioXcel Clinical Research Site
City
Toms River
State/Province
New Jersey
ZIP/Postal Code
08755
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

We'll reach out to this number within 24 hrs